Johnson & Johnson is reportedly considering a potential sale of its orthopedics unit, Bloomberg reported Feb. 19.
In October, Johnson & Johnson announced its initial plans to separate the orthopedics business, DePuy Synthes. At the time, the company said it expected to complete that separation within 18 to 24 months.
Sources familiar with the matter told Bloomberg that the company is preparing documents and financials ahead of meetings with potential buyers in the coming weeks. Several large private equity firms are weighing a collaboration to buy out DePuy Synthes, which could be valued at more than $20 billion, Bloomberg reported.
Deliberations are at an early stage, the report said.
Johnson & Johnson declined to comment to Bloomberg.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
